anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive teclistamab SC on days 1, 4, 7, 15 and 22 for cycle 1 and days 1, 8, 15 and 22 for remaining cycles. Patients also receive iberdomide PO QD on days 1-21 for cycle 2 and beyond. Cycles repeat every 28 days for up to 4 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood and urine sample collection, bone marrow aspiration and biopsy and CT, PET/CT or MRI throughout the trial.
Isolated genomic DNA molecule having a defined nucleic acid sequence and encoding an antigenic protein (I) derived from Eimeria tenella is new. (I) has a molecular wt. of about 25000 daltons and is composed of two polypeptides joined by a disulphide bond. One polypeptide has a molecular wt. of about 17000 daltons, has a blocked N-terminal amino acid and a defined amino acid sequence. The other polypeptide has a molecular wt. of about 8000 daltons and a defined amino acid sequence.
BACKGROUND: A central giant cell granuloma (CGCG) is a benign, proliferative, intraosseous, and non-odontogenic lesion occurring primarily in children and young adults. On the histological level, it is characterized by numerous multinucleated giant cells scattered randomly throughout a sea of spindle-shaped mesenchymal stromal cells which are dispersed throughout the fibrovascular connective tissue stroma containing areas of haemorrhage. When it comes to radiographic features, CGCG can have an array of variations, ranging from well-defined expansile lesions to ill-defined and destructive lesions, with or without expansion.
CASE PRESENTATION: This case report reviews an 11-year-old Caucasian patient with a chief complaint of slow-growing swelling involving the right posterior mandibular region. The cone beam computed tomography (CBCT) revealed an ill-defined mixed lesion mimicking both fibro-osseous lesion and hemangioma. However, microscopic examination revealed multinucleated giant cells in a fibrous stroma suggestive of central giant cell granuloma.
CONCLUSION: Our intent in reporting this case is to highlight the importance of thorough clinical, radiographical and histopathological examination for accurate diagnosis and therapeutic interventions as well as to emphasize the importance of taking different possibilities into consideration when examining bony swellings in the head and neck region.
At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
BACKGROUND: Antibiotic cement spacers have been widely used in the treatment of joint infections. There are no commercially available antibiotic spacers for the elbow. Instead, they are typically fashioned by the surgeon at the time of surgery using cement alone or a combination of cement with sutures, Steinmann pins, external fixator components, or elbow arthroplasty components. There is no consensus regarding the ideal elbow antibiotic spacer and no previous studies have examined the complications associated with these handmade implants in relation to their unique structural design.
METHODS: We retrospectively reviewed 55 patients who had 78 static antibiotic cement spacers implanted between January 1998 and February 2021 as part of a 2-stage treatment plan for infection of an elbow arthroplasty, other elbow surgery, or primary elbow infection. Several antibiotic spacer structures were used during the study period. For analysis purposes, the spacers were classified into linked and unlinked spacers based on whether there was a linking mechanism between the humerus and the ulna. Complications related to these spacers that occurred either during the implantation, between implantation and removal, or during removal were recorded and analyzed from chart review and follow-up x rays. Reoperations due to spacer-related complications were also recorded.
RESULTS: Among the 55 patients (78 spacers), there were 23 complications, including 17 minor and 6 major complications. The most common complication of unlinked spacers (intramedullary [IM] dowels, beads and cap spacer) was spacer displacement. Other complications included IM dowel fracture and difficulty locating beads during spacer removal. The major complications of linked cement spacers included two periprosthetic humerus fractures after internal external fixator cement spacers and re-operation due to breakage and displacement of one bushing cement spacer. The major complications of unlinked cement spacers included two reoperations due to IM dowel displacement and one reoperation due to displacement of beads. Among patients who had removal of all components and those with native joints, there was no statistically significant difference between internal external fixator cement spacers and unlinked cement spacers in minor complication rates (30% vs. 16%, P = .16), major complication rates (7% vs. 8%, P = .85) and reoperation rates (0% vs. 8%, P = .12).
CONCLUSIONS: Static handmade antibiotic elbow spacers have unique complications related to their structural designs. The most common complication of linked and nonlinked cement spacers were failure of the linking mechanism and displacement, respectively. Surgeons should keep in mind the possible complications of different structures of cement spacers when choosing 1 antibiotic spacer structure over another.
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of the upper gastrointestinal tract. Thus, the invention provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract, including inflammatory diseases. GLP-2 stimulates the growth of upper gastrointestinal tissue when administered in conjunction with other peptide hormones. The invention further provides pharmaceutical compositions of GLP-2 with at least one other peptide hormone, methods of enhancing the growth of upper gastrointestinal tissue and of gastrointestinal disorders by increasing serum levels of GLP-2 and at least one other peptide hormone, an kits for performing the methods of the invention.
Staphylococcus aureus is a notorious pathogen responsible for various severe diseases. Due to the emergence of drug-resistant strains, the prevention and treatment of S. aureus infections have become increasingly challenging. Vancomycin is considered to be one of the last-resort drugs for treating most methicillin-resistant S. aureus (MRSA), so it is of great significance to further reveal the mechanism of vancomycin resistance. VraFG is one of the few important ABC (ATP-binding cassette) transporters in S. aureus that can form TCS (two-component systems)/ABC transporter modules. ABC transporters can couple the energy released from ATP hydrolysis to translocate solutes across the cell membrane. In this study, we obtained a strain with decreased vancomycin susceptibility after serial passaging and selection. Subsequently, whole-genome sequencing was performed on this laboratory-derived strain MWA2 and a novel single point mutation was discovered in vraF gene, leading to decreased sensitivity to vancomycin and daptomycin. Furthermore, the mutation reduces autolysis of S. aureus and downregulates the expression of lytM, isaA, and atlA. Additionally, we observed that the mutant has a less net negative surface charge than wild-type strain. We also noted an increase in the expression of the dlt operon and mprF gene, which are associated with cell surface charge and serve to hinder the binding of cationic peptides by promoting electrostatic repulsion. Moreover, this mutation has been shown to enhance hemolytic activity, expand subcutaneous abscesses, reflecting an increased virulence. This study confirms the impact of a point mutation of VraF on S. aureus antibiotic resistance and virulence, contributing to a broader understanding of ABC transporter function and providing new targets for treating S. aureus infections.
In exemplary embodiments, an on-body medical device has an adhesive layer with adhesives of two or more strengths. In some of the exemplary embodiments, a stronger adhesive is positioned on the adhesive layer where additional strength is needed, such as around the perimeter of the adhesive layer to prevent premature peeling. A weaker adhesive is positioned on other portions of the adhesive layer where there is no need for the strength of the stronger adhesive. In other exemplary embodiments, three strengths of adhesives are used on the adhesive layer. An intermediate strength adhesive is used along with a stronger adhesive and a weaker adhesive. The intermediate strength adhesive may be used in areas where the weaker adhesive does not provide enough strength but the full strength of the stronger adhesive is not needed.
PROBLEM TO BE SOLVED: To obtain the subject pack improved in sticky feeling after used, and useful for promoting the active ingredient absorption and/or removing excessive sebum or the like. SOLUTION: This pack is obtained by including a silicone, pref. in the form of a methylpolysiloxane emulsion containing a high-polymerization degree polymethylsiloxane; wherein it is preferable to include no acrylic polymer in this pack. This pack has pref. such a design that a substrate such as a nonwoven fabric is impregnated with a fluid composition containing the above silicone. This composition may optionally be formulated with e.g. such active ingredient(s) as glycerol, isoprene glycol and/or collagen other than the above silicone. The content of the above silicone in this pack is pref. 0.01-10 wt.%, more pref. 0.05-5 wt.% based on the total amount exclusive of the above substrate.
PURPOSE: To obtain a make-up set containing one-time amount used and provided with a distributor pre-filled with cosmetics by composing a package with two sheets partially welded with each other and forming a narrowing area between the feeder holder and distributor. CONSTITUTION: This tightly-sealed set 1 is formed by welding two plastic sheets 2a, 2b made from a polymer selected according to the cosmetic prescription. The plastic sheets 2a, 2b have chemical compatibility with the cosmetics contained in the distributor. They are welded by heat or ultrasonic wave. This make-up set 1 is formed into a rectangle in the plan view; consists of two parts 13, 14; the part 13 has the first not-welded area 13a and the second area where is joined mutually via the weld beads 6 that can easily to torn off by hands. The sheets 2a, 2b form a volume sectioned by each sidewall 4a, 4b of half-shell type. The volume 4 is made to have a finely smaller diameter in the narrowing area 7 than the minimum outside diameter of the brush bristles.
PURPOSE:To manufacture a titled compd. carrying a small amt. and many kinds of dissolved mineral constituents by mixing and reacting an aq. soln. of sodium silicate, an aq. soln. of aluminum salt, and a mother liquid of desalted seawater. CONSTITUTION:An aq. soln. of sodium silicate, an aq. soln. of an aluminum salt, and a mother liquid of desalted seawater are mixed and reacted simultaneously or intermittently. Since said mother liquid is used as a magnesium source and also contains a small amt. and many kinds of mineral constituents, an activated magnesium aluminosilicate carrying said minerals can be obtained. The magnesium aluminosilicate, having a powerful anti-acidic function at 3-5pH, is especially effective as an anti-acid preparation, and is also effecive as a tonic medicine of digestive organs in cooperation with other trace mineral constituents differently from an existing anti-acid preparation of a methamagnesium aluminosilicate series. The product is available as a carrier for other medicines, a food additive, a feed additive, cosmetics (white pigment), etc.
INTRODUCTION: This study aimed to evaluate the effect of coronavirus disease (COVID-19) on the patients' referral in the pregnant population and also investigate each treatment approach's advantages and disadvantages for acute renal colic in pregnancy.
METHODS: In this retrospective study, we included all pregnant women with ureteral stones referred to a referral center between January 2019 and March 2021.
RESULTS: Among 53 pregnant women, 18 (33.9%) were on conservative therapy, which passed the stone without any complications. Double J stent or nephrostomy tube insertion was done for 24 patients (45.2%). Seventeen of these patients (70.8%) presented post-surgical complications, including hematuria (29.2%), pyelonephritis (20.8%), and lower urinary tract symptoms (20.8%). Transurethral lithotripsy (TUL) was done in 11 patients (20.7%). Only one of these patients developed hematuria following TUL. Thus, in our population study, double J stent or nephrostomy insertion was associated with a higher chance of postoperative complications than TUL (p-value = 0.001). Thirty-six patients were referred within 13 months before the entry of COVID-19, while 17 were referred during a similar approximate duration after the COVID-19 entry into the country. Only the initial presentation had a significant difference between these two periods (p-value = 0.034).
CONCLUSIONS: When conservative treatment fails, we recommend TUL as the second-line treatment over temporary procedures, such as double J stent or nephrostomy insertion. Of note, in a group of patients with an emergent clinical setting, including active infection, deteriorating renal function, signs of preterm labor, solitary kidney, etc., double J or nephrostomy tube insertion remains the preferred management method for its fast resolution of obstruction and infection. Besides, a decrease in visits with an increase in complicated cases after COVID-19 was observed, maybe due to a delay in referring.
A system and method for providing a computed radiography (CR) system customer with a recommended CR system and/or CR system configuration. The recommended CR system being established by a customer's responses to a plurality of questions. The system has a product selector file and a product configuration file. The product selector file provides a query page with the plurality of questions to be answered by the customer. The product configuration file having a plurality of predicted system values. A Java applet being used to compare the customer's responses to the plurality of questions to the predicted values. The product configuration file supplying a results page with the recommended system.
FIELD: chemical technology, vitamins. SUBSTANCE: method involves condensation of azoribitylamine with barbituric acid in medium of aliphatic alcohol in the presence of acetic acid at boiling point. Process is carried out in the presence of water addition taken at mass ratio barbituric acid : water = 1:(0.6-1.2). The source of aliphatic alcohols: alcohols showing acidity that is equal or above that of isopropanol. Process is carried out at homogeneous phase without use of absolute solvents. EFFECT: simplified process, increased yield, decreased time of process. 2 cl, 1 tbl
BACKGROUND: Immune checkpoint blockade (ICB) therapy provides remarkable clinical benefits for multiple cancer types. However, the overall response rate to ICB therapy remains low in esophageal squamous cell carcinoma (ESCC). This study aimed to identify biomarkers of ICB therapy for ESCC and interrogate its potential clinical relevance.
METHODS: We investigated gene expression in 42 treatment-naïve ESCC tumor tissues and identified differentially expressed genes, tumor-infiltrating lymphocytes and immune-related genes signatures associated with differential immunotherapy responses. We systematically assessed the tumor microenvironment using the NanoString GeoMx digital spatial profiler, single-cell RNA-seq and multiplex immunohistochemistry in ESCC. Finally, we evaluated the associations between HLA-A-positive tertiary lymphoid structures (TLSs) and patients' responses to ICB in 60 ESCC patients.
RESULTS: Tumor infiltrating B lymphocytes and several immune-related gene signatures, such as the antigen presenting machinery (APM) signature, are significantly elevated in ICB treatment responders. Multiplex immunohistochemistry identified the presence of HLA-A+ TLSs and showed that TLS-resident cells increasingly express HLA-A as TLSs mature. Most TLS-resident HLA-A+ cells are tumor-infiltrating T (TIL-T) or tumor-infiltrating B (TIL-B) lymphocytes. Digital spatial profiling of spatially distinct TIL-T lymphocytes and single-cell RNA-seq data from 60 ESCC tumor tissues revealed that CXCL13-expressing exhausted TIL-Ts inside TLSs are reactivated with elevated expression of the APM signature as TLSs mature. Finally, we demonstrated that HLA-A+ TLSs and their major cellular components, TIL-Ts and TIL-Bs, are associated with a clinical benefit from ICB treatment for ESCC.
CONCLUSIONS: HLA-A+ TLSs are present in ESCC tumor tissues. TLS-resident TIL-Ts with elevated expression of the APM signature may be reactivated. HLA-A+ TLSs and their major cellular components, TIL-Ts and TIL-Bs, may serve as biomarkers for ICB-treated ESCC patients.
1. Technical Result Producing human monoclonal antibodies against human cytotoxic T-lymphocyte antigen. 2. Essence In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chains of said antibodies. Further provided is a method for production of said antibodies and their use for inhibiting increase in producing cytokines in T-cells and for inhibiting tumor growth. 3. Field of Application Immunology, medicine.
A stent (100) is formed from a wire (102) that in cross-section includes an outer member (102) having a lumen (103) and a radiopaque core member (124) partially filling the lumen. A therapeutical substance (112) for elution through openings formed through the outer member fills the portion of the lumen not filled by the radiopaque core member. In a method of forming the stent, a composite wire including an outer member and a dual core member is shaped into a stent pattern. The dual core member includes a first core member and a second, radiopaque core member. The shaped composite wire is processed to remove the first core member from the outer member without adversely affecting the outer member and the second core member. The portion of the lumen that was occupied by the first core member may be filled with a substance for elution through openings from through the outer member to the lumen.
Endoscopic ultrasound has become the preferred method to characterise gastrointestinal (GI) wall and peri-gastrointestinal masses. A major strength is that it can be used to guide fine needle aspiration (EUS-FNA) of any lesion in the wall or within 5cm from the GI tract. However, EUS-FNA has a major drawback- it rarely able to provide tissue blocks. Thus multiple passes, each of them time consuming, are necessary to obtain adequate cellular samples for cytological analysis. A radically new design of FNA needle (AcquireTM) has recently become available. The needle has an additional cutting edge surface, which allows better tissue access and acquires intact large core samples. The flexibility of the needle permits its use in tortuous anatomy, thereby making it an ideal needle for FNA. The new AcquireTM fine needle biopsy device (FNB) provides core tissue (\>90%) for histology. This ability of the needle will enable us to obtain core tissue in fewer passes and make a precise diagnosis. However, at present there is no prospective randomized study to validate this finding.

The investigators hypothesize that the unique cutting system of Acquire TM fine needle biopsy (FNB) device will improve the specimen adequacy of solid intestinal and extra-intestinal lesions by providing a good core tissue for analysis.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of HERCEPTIN or of other trastuzumab products.

Among 903 women with metastatic breast cancer, human anti human antibody (HAHA) to Herceptin was detected in one patient using an enzyme linked immunosorbent assay (ELISA). This patient did not experience an allergic reaction. Samples for assessment of HAHA were not collected in studies of adjuvant breast cancer.

The clinical relevance of the development of anti-trastuzumab antibodies after treatment with HERCEPTIN is not known.
BACKGROUND: The Gran Chaco ecoregion is a well-known hotspot of several neglected tropical diseases (NTDs) including Chagas disease, soil-transmitted helminthiasis and multiparasitic infections. Interspecific interactions between parasite species can modify host susceptibility, pathogenesis and transmissibility through immunomodulation. Our objective was to test the association between human co-infection with intestinal parasites and host parasitaemia, infectiousness to the vector and immunological profiles in Trypanosoma cruzi-seropositive individuals residing in an endemic region of the Argentine Chaco.
METHODS: We conducted a cross-sectional serological survey for T. cruzi infection along with an intestinal parasite survey in two adjacent rural villages. Each participant was tested for T. cruzi and Strongyloides stercoralis infection by serodiagnosis, and by coprological tests for intestinal parasite detection. Trypanosoma cruzi bloodstream parasite load was determined by quantitative PCR (qPCR), host infectiousness by artificial xenodiagnosis and serum human cytokine levels by flow cytometry.
RESULTS: The seroprevalence for T. cruzi was 16.1% and for S. stercoralis 11.5% (n = 87). We found 25.3% of patients with Enterobius vermicularis. The most frequent protozoan parasites were Blastocystis spp. (39.1%), Giardia lamblia (6.9%) and Cryptosporidium spp. (3.4%). Multiparasitism occurred in 36.8% of the examined patients. Co-infection ranged from 6.9% to 8.1% for T. cruzi-seropositive humans simultaneously infected with at least one protozoan or helminth species, respectively. The relative odds of being positive by qPCR or xenodiagnosis (i.e. infectious) of 28 T. cruzi-seropositive patients was eight times higher in people co-infected with at least one helminth species than in patients with no such co-infection. Trypanosoma cruzi parasite load and host infectiousness were positively associated with helminth co-infection in a multiple regression analysis. Interferon-gamma (IFN-γ) response, measured in relation to interleukin (IL)-4 among humans infected with T. cruzi only, was 1.5-fold higher than for T. cruzi-seropositive patients co-infected with helminths. The median concentration of IL-4 was significantly higher in T. cruzi-seropositive patients with a positive qPCR test than in qPCR-negative patients.
CONCLUSIONS: Our results show a high level of multiparasitism and suggest that co-infection with intestinal helminths increased T. cruzi parasitaemia and upregulated the Th2-type response in the study patients.